@entity12698 for the prevention of nonmuscle invasive XXXX : results from a matched control study.

@entity1 @entity12698 @entity5 @entity1138 @entity1139 @entity150 @entity3840
OBJECTIVES: New targets and approaches are under investigation for the treatment of nonmuscle invasive @entity150 (NMIBC). Preclinical data suggest @entity3840 ( @entity3840 ) as a promising target. @entity12698 , a @entity3840 selective inhibitor, inhibits @entity5 development and enhances survival, both in vitro and in vivo models of @entity150 . Therefore, we conducted a pilot study of @entity12698 to prevent recurrence in @entity1 with intermediate risk NMIBC. METHODS: Treatment with @entity12698 was administered orally for 12 months and compared with a contemporary series of @entity1 treated with intravesical @entity1138 ( @entity1139 ), given weekly for 4 weeks and then monthly for 11 months. Primary endpoints were time to first recurrence and adverse events. RESULTS: From 2003 through 2006, 58 @entity1 were treated with @entity12698 and compared with 66 @entity1 receiving @entity1139 . After a median follow up of 75 months, 49 @entity1 were disease free, including 23 (34.85%) in the @entity1139 group and 26 (44.8%) in the @entity12698 group. Median disease-free interval was 67 months [95% confidence interval (CI) 35.8 to NA] versus 41 months (95% CI 27.1-67.1; log-rank p = 0.25) for @entity1 treated with @entity1139 and @entity12698 , respectively. In the multivariate analysis, treatment was not found to be an independent predictor for recurrence [hazard ratio (HR) 0.76, 95% CI 0.47-1.22, p = 0.25). Overall, 45 AEs were recorded in 35/124 @entity1 . There were no differences between the two groups. CONCLUSIONS: Our data support a clinical benefit of @entity12698 and encourage future trials in which @entity3840 inhibitors may be tested in selected @entity1 with NMIBC.
